the discovery and development of liraglutide and semaglutide [TUSOM Semaglutide as a GLP-1 Agonist:

Results showed significantly accelerated and increased bone formation in non-healing femoral defects compared to uncoated scaffolds and empty defects

They also slow down how fast food leaves the stomach, helping you feel full longer

The obesity segment is the fastest-growing application during forecast period, fueled by increasing global obesity prevalence and expanding FDA and EMA approvals of GLP-1 drugs specifically for weight loss

Limitations of Use: Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist The safety and efficacy of coadministration with other products for weight loss have not been established Wegovy has not been studied in patients with a history of pancreatitis Who should not use Wegovy